By Tina Reed
Overall, total hospital admissions dropped as low as 69% of predicted levels during the second week of April as stay-at-home orders required elective surgeries to be canceled, according to electronic medical record data from the Epic Health Research Network.
read more
By Eric Sagonowsky
The countdown to the FDA's first coronavirus vaccine hearing has begun. More than seven months into the COVID-19 pandemic, with several vaccines in late-stage testing and developers preparing to file for widespread use, the FDA unveiled its plan for a Thursday advisory panel confab.
read more
By Angus Liu
An inhaled neutralizing antibody cleared the novel coronavirus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies. The drug is now being developed by Aridis Pharmaceuticals and could offer a self-administered option for COVID-19 if it succeeds in human testing.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
AstraZeneca's U.S. trial could resume this week, Reuters reports. Sinovac's shot proved safe after two doses, early phase 3 data showed. The FDA will set a "level playing field" for vaccine reviews at Thursday's AdComm confab. And Black Americans have grown more skeptical of a shot, The Harris Poll found.
read more
By Paige Minemyer
Cigna and MDLive have joined forces to offer virtual wellness exams with the hope that these visits will serve as an on-ramp for patients who rarely interact with the healthcare system.
read more
By Beth Snyder Bulik
Black Americans’ confidence in COVID-19 vaccines is plummeting. Only 43% of Black Americans now say they will get a vaccine once it's available, down 22 percentage points since August, The Harris Poll found.
read more
By Robert King
The premiums for benchmark plans sold on the ACA's exchanges via HealthCare.gov are expected to decline by 2% in 2021 and more insurers are expected to sell plans, a new report finds.
read more
By Ben Adams
The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new chief medical officer.
read more
